Anti-obesity Drugs Market in the US 2015-2019
Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.
Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.
Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Anti-obesity Drugs Market in the US 2015-2019
Technavio recognizes the following companies as the key players in the Anti-obesity Drugs Market in the US: Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics and Vivus
Other Prominent Vendors in the market are: Alizyme, Amylin, Boehringer Ingelheim, Eisai, Merck, Norgine, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical and Zafgan
Commenting on the report, an analyst from Technavio’s team said: “Many anti-obesity drugs have been issued complete response letters (CRLs) by the FDA before approval. For instance, the FDA issued a CRL to Takeda/Orexigen Therapeutics's Contrave in 2010, which requested further details regarding the cardiovascular safety profile of the drug when used over the long term in a population of overweight and obese subjects. Similarly, Vivus/Eisai's Qsymia was also issued a CRL, which requested further details regarding the clinical label, Risk Evaluation and Mitigation Strategy, safety update, and drug scheduling data. Thus, stringent regulations will hamper market growth.”
According to the report, Epidemiological statistics clearly signify that the target population for anti-obseity drugs is huge. In addition, advances in medical technologies have led to a rise in the number of people diagnosed with obesity. Thus the high number of overweight people coupled with improved diagnostics will drive the growth of the market.
Further, the report states that enormous R&D expenses coupled with high attrition rates pose a major challenge to the discovery and development of anti-obesity drugs.
Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Vivus, Alizyme, Amylin, Boehringer Ingelheim, Eisai, Merck, Norgine, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Zafgan
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook